Arctoris welcomes on board world-renowned experts in machine learning, chemical computing and Alzheimer’s disease
OXFORD, England–(BUSINESS WIRE)–Arctoris Ltd, a technology-based biopharmaceutical platform company, has named three globally recognized experts in Alzheimer’s disease, machine learning applied to closed-loop discovery and automated chemistry as as members of its Scientific Advisory Board: Professor John Davis (University of Oxford), Professor Rafael Gómez Bombarelli (MIT) and Dr Teodoro Laino (IBM Research).
“We are delighted to have Professor Davis, Professor Gómez Bombarelli and Dr. Laino join our company’s Scientific Advisory Board at this exciting time in Arctoris’ growth,” said Martin-Immanuel Bittner MD DPhil FRSA FIBMS, CEO and co-founder of Arctoris. “Professor Davis is a world-renowned expert in dementia research, while Prof. Gómez Bombarelli and Dr. Laino are pioneers in chemical computation and accelerated discovery. Both of these areas are critical to our technology and pipeline development, and we are grateful for the support of these highly distinguished individuals. »
John Davis is Scientific Director of the Center for Medicines Discovery (Oxford) and Director of Business Development for Alzheimer’s Research UK – Drug Discovery Alliance. He has over 25 years of drug discovery expertise, from target identification to successful clinical proof of concept for a range of drug candidates in neurological disorders. After postdoctoral training at the Ludwig Institute and the Salk Institute, he joined GlaxoSmithKline where he led various non-clinical pharmacology research departments on pain and neurodegenerative diseases. In 2010, Professor Davis co-founded spin-off company Convergence Pharmaceuticals, which he later left to become Director of Discovery for Selcia, and CSO and co-founder of Cypralis before joining Oxford University.
Rafael Gómez Bombarelli is the Jeffrey Cheah Assistant Professor of Engineering in the Department of Materials Science and Engineering at MIT. His research focuses on accelerated discovery cycles and machine learning approaches for molecular design and optimization. Professor Gómez Bombarelli’s work has been published in journals such as Science, Nature Chemistry and Nature Materials, and has been featured in MIT Technology Review and the wall street journal. He earned a bachelor’s, master’s, and doctorate in chemistry from the University of Salamanca, followed by postdoctoral work at Heriot-Watt University, Harvard University, and Kyulux North America before taking up his post. at MIT.
Teodoro Laino leads chemical computing and automated synthetic chemistry efforts in the Cognitive Computing and Industrial Solutions department at IBM’s Zurich Research Lab. He is interested in applying machine learning to chemistry and materials science problems with the goal of developing scalable and technological solutions to dramatically improve chemical synthesis (e.g. IBM RXN for chemistry). A chemist by training, Dr. Laino holds a doctorate in computational chemistry, after which he worked as a post-doctoral researcher at the University of Zurich developing algorithms for the simulation of molecular dynamics.
New Scientific Advisory Board member John Davis said, “Neurodegenerative diseases and in particular Alzheimer’s disease is an area of significant unmet clinical need. As a company, Arctoris’ strategy and direction for developing its portfolio of assets is governed by the best scientific and clinical evidence in the field, and I am delighted to support their scientific and management team with expertise in the therapeutic area.
“Finding effective ways to accelerate the Design-Build-Test-Analyze cycle is crucial for the rapid development of new and improved materials or treatments. Working with Arctoris, my team at IBM Research has spent the past two years exploring potential integrations between our own IBM Research Accelerated Discovery platform and Arctoris’ own flagship technology, Ulysses. Today, I am delighted to announce that I will be an expert in automated synthesis and machine learning modeling in chemistry on the Arctoris Scientific Advisory Board, furthering our mutually beneficial collaboration,” said Teodoro Laino.
“My research focuses on accelerated discovery and optimization of molecular design, and I believe that Arctoris’ Ulysses platform and its combination of wet lab and dry lab approaches are the future of drug discovery. small molecules. I am excited to bring my expertise in closed loop and machine learning approaches to accelerated scientific discovery, where Arctoris is building a truly unique platform and business,” said Rafael Gómez Bombarelli.
ABOUT ARCTORIS LTD
Arctoris is a technology-based biopharmaceutical platform company founded and headquartered in Oxford, UK, with its US operations based in Boston and its Asia Pacific operations based in Singapore. Arctoris combines robotics and machine learning with a world-class team for accelerated discovery of small molecules. Ulysses, the unique technology platform developed by Arctoris, allows the company and its partners to conduct their R&D – from target to hit, lead and candidate – much faster, and with quality and depth of significantly improved data. The company’s end-to-end automation platform is capable of generating large and accurate datasets across hundreds of experiment and assay types. The resulting data assets are captured and transmitted through automated analytical pipelines and feed directly into Arctoris’ machine learning capabilities, creating powerful predictive models that can identify superior molecules faster. Bringing together the expertise of seasoned biotech and pharmaceutical industry veterans with its proprietary technologies, Arctoris leads to higher success rates and accelerated program progression to the clinic. Arctoris pursues an in-house pipeline of oncology and neurodegeneration assets and also collaborates with selected biotech and pharma partners in the United States, Europe and Asia-Pacific, including several Top 10 Pharma.
For the latest updates, visit www.arctoris.com and follow us on LinkedIn
